Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
Location:Home > Pharma China Web Edition > Other News    
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
WiCON International Group
311 Sayre Drive,
Princeton, NJ 08540, USA
Tel/Fax: +1 702-9953905
Email:
info@pharmachinaonline.com

China Head Office
c/o Beijing Jicai PharmTech
Suite B-17D, Oriental Kenzo Plaza
48 Dongzhimenwai Dajie
Dongcheng District
Beijing 100027, China
Tel: +86 10 84476010
Fax: +86 10 84476010
Email:
info@pharmachinaonline.com
 
 
 
Other News
 
Upcoming Event: Pharma China Annual Forum 2017 in Shanghai on April 14
 
2-14-2017

Event: Pharma China Annual Forum 2017
Organizer: Pharma China
Sponsor(s): RDPAC, Kantar Health, Others TBA
Date: 9 AM to 5:15 PM, April 14, 2017
Venue: Le Royal Meridien Shanghai, China
Weblinkhttp://www.pharmachinatraining.com/coursedetail8.html
Event brochurePCAF 2017 Brochure+Registration+Sponsorship.pdf

Fees: CNY 6,000 ($900) for Pharma China subscribers and employees of RDPAC member companies. CNY 6,500 ($980) for others (credit card acceptable at 3% charge for US$ payments)

Bonus: All participants will receive a free copy of Pharma China Annual Review and Outlook 2016/2017, as well as the latest issue of Pharma China Journal Edition

Contact: Jenny Wang or David Xue
Tel: +86 10 84476010
Cell: +86 18601267831
Fax: +86 10 84476110
Email: jenny.wang@pharmachinaonline.com and dxue@pharmaguys.com

Event Highlights

- Contemporary trends & issues in Chinese Pharma in 2016 and early 2017
- Business, healthcare reform and regulatory outlook for 2017 and beyond
- Changing dynamics in Chinese pharma/healthcare landscape
- Evolving new business model and pharma sales & marketing strategies
- Trends and strategies for market access, drug R&D, partnership and licensing
- Interactive discussion and brainstorming with our panel of top experts

Introduction

Each year there are more uncertainties surrounding China healthcare and 2017 is no exception. The pharmaceutical industry in China is facing an overhaul of its business model, fast changing marketplace and repeated assaults of its bottomlines. 

The Chinese pharmaceutical industry revenue and profit growth rebounded slightly in 2016 to 10.3% and 15.6% respectively in 2016 despite shadows of numerous challenges stemmed from the troubled Chinese economy, regulatory shakeups, cost containment measures and healthcare reform turbulences, according to CPIIC. On the other hand, SMEI suggests the Chinese pharmaceutical market rose slower in 2016 at only 8.76%, compared with 11.0% in 2015. Albeit the seemingly better industry performance, which may simply mean higher inventory in the face of slower market growth, the era of single-digit Chinese pharmaceutical market growth has finally arrived.

The pharma e-commerce segment has been brewing major revolutionary developments. Despite temporary setbacks for official liberalization of online prescription drug sales in 2016, its prospects are sharply uplifted by government withdrawal of approval requirements for pharma B2B and B2C businesses in early 2017. By now, most leading players are well-positioned to take advantage of potential opportunities.

In the meantime, the CFDA’s move to elevate drug quality and reform drug approval system, though contradicted by other government agency’s preoccupation to slash drug costs, has advanced substantially in the past year. The real questions are that, with the world’s largest population, what kind of healthcare solution and product mix China can and should get for merely 5%-6% of GDP? Is the country willing or able to pay more for better drugs and healthcare being pushed? 

On the front of drug pricing, the NDRC returned to the drug pricing theme in 2016 under a different flag of antitrust enforcements. By late 2016, the MOHRSS also finalized its draft policy for proposed uniform BMI payment standards and initiated the process to revise the National Drug Reimbursement List.

Despite superficial slogans and touted ambitions of the Chinese government, the healthcare reform has been hijacked by cost containment and gone astray from the pledged path of improving efficiency and fixing structural flaws.

With tax and other revenues drying up and under increasing threat of BMI system deficit amid a slowing Chinese economy, local governments are pressured by both the central government and the public to do more for healthcare with less financial resources. 

Pushed to the corner, the Chinese pharmaceutical industry is now at the brink of business bottomlines. Under pressures of escalating anti-corruption campaigns, increasingly sophisticated cost containment measures as well as policy shifts in drug pricing and reimbursements, both domestic and multinational drug companies had no choice but to recalibrate their strategies and business models in order to meet the challenges of the Chinese healthcare business today. 

Nonetheless, many drug company executives are still bullish about China's long-term growth prospects. As the government improves access to healthcare, the country’s pharmaceutical market is projected by IMS to reach approximately between $140 billion and $170 billion by 2021 on slower annual growth between 5% and 8%. But the short-term picture is proving difficult, with reforms in the hospital sector affecting physician prescriptions and price pressures growing for most drugs.

The Chinese economy and the reform of its healthcare system are once again at crossroads. Pharma companies, local or foreign, must change to remain competitive and fit with the market.

The Pharma China Annual Forum 2017 is an English language annual pharma industry event oriented for foreign drug companies in China. It is sponsored by RDPAC and WiCON International Group LLC, the publisher of WiCON|Pharma China. The event’s emphasis is on healthcare policies, drug regulations, market access and strategic issues as well as potential impacts of latest and upcoming policy changes on the Chinese pharma industry. In addition, contemporary trends of M&As, R&D and licensing, business hotspots and e-commerce, as well as future market outlook will be explored and discussed. 

At least 10 leading experts will share their knowledge, insights and expertise. The presentation will be followed by an interactive panel discussion with speakers and other experts.

Fee (covering attendance, lunch and refreshments)
CNY 6,000 – Pharma China subscribers and employees of RDPAC member companies
CNY 6,500 – All other non-subscribers of Pharma China

Sponsorship opportunities

Please contact us about sponsorship packages for refreshments and after-event cocktail.

Registration

Spaces are limited to 60 participants and priority is given to WiCON|Pharma China subscribers. Please contact:

Jenny Wang
Tel: +86 10 8447-6010 Fax: +86 10 8447-6110
Email: jenny.wang@pharmachinaonline.com or jwang.wicon@gmail.com

David Xue
Tel: +86 10 8530-0937 Cell: +86 18601267831
Email: dxue@pharmaguys.com

 
 
Relate News  
 
 
 
 
 
© Wicon International Group  Support by: www.heightow.com   Site map | Contact Us | Links